Molecular-targeted therapy for chemotherapy-refractory gastric cancer: A case report and literature review

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3695-3699

  Kuo, Hung Yang ^a   Yeh, Kun Huei ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Gastric cancer; Ramucirimab; Refractory; Targeted therapy; Trastuzumab

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; RAMUCIRUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; DISEASE DURATION; DISTANT METASTASIS; DRUG MEGADOSE; EPIGASTRIC PAIN; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LYMPHADENOPATHY; MALE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; ROUX Y ANASTOMOSIS; SALVAGE THERAPY; STOMACH CANCER; TOTAL STOMACH RESECTION; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; RAMUCIRIMAB; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY; STOMACH TUMOR; TARGETED THERAPY;

CHEMOTHERAPY; GASTRIC CANCER; RAMUCIRIMAB; REFRACTORY; TARGETED THERAPY; TRASTUZUMAB;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84906319290     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER Cancer Statistics Review, 1975-2009. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
3. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G and Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47: 2306-2314, 2011.
4. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK and Park SH: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30: 1513-1518, 2012.
5. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM and Dunn JA: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase III randomised controlled trial. Lancet Oncol 15: 78-86, 2014.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
7. Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, Hwang TL, Jan YY and Yeh TS: Impact of HER2 overexpression/ amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist 16: 1706-1713, 2011
8. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, and Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
9. Yeh KH, Shen YC, Li CR, Yen CJ, Lin YL, Lin ZZ, Chen LT, Su WC, Chao Y, and Cheng AL: Phase II study of low-dose everolimus plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for first-line treatment of metastatic or recurrent gastric cancers. Eur J Cancer 47: S467, 2011.
10. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, and Kang YK: Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976, 2011.
11. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, and Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase III trial. Lancet Oncol 14: 490-499, 2013.
12. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C and Barbachano Y: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase III trial. Lancet Oncol 14: 481-489, 2013.
13. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 10: 643-655, 2013.
14. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D and Van Cutsem E: Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31 : 3935-3943, 2013.
15. Bang YJ: A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study J Clin Oncol 31(14 Suppl): abstract 11, 2013.
16. Sun GP, Sun Y, Xu RH, Xu JM, Li J, Wang JW, Qin S, Feng JF, Ba Y, Shen L, Bai YX, Sun Y, Pan H, Cheng Y, Yu S, Zhong H, Bai L, Luo R, Kobayashi M and Ohtsu A: The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries. J Clin Oncol 31(15 Suppl): abstract 4109, 2013.
17. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD and Tabernero J: REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase III trial. Lancet 383: 31-39, 2014.
18. Shitara K, Yatabe Y, Yokota T, Takahari D, Shibata T, Ura T, Satoh Y, Kodera Y, and Muro K. Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis. Gastrointest Cancer Res 5: 97-99, 2012.
19. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00680901, 2013.